ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
Aptus Pharma Limited submitted its Monitoring Agency Report for the period ended March 31, 2026, confirming full utilization of ₹13.02 Crore raised through its IPO. The report, issued by CARE Ratings Limited, shows NIL deviation from the objects stated in the offer document, covering working capital, capital expenditure, and corporate purposes.
Aptus Pharma Limited submitted its statement of utilization of IPO proceeds for the period ended March 31, 2026. The company confirmed it raised and fully utilized ₹13.02 Crore across objects including working capital and capital expenditure, reporting zero deviation or variation.